Harvard Business School professors discuss and debate current events that sit at the crossroads of b
Youngme Moon , Felix Oberholzer-Gee , and Mihir Desai debate whether former Nissan executive Carlos
Youngme Moon , Felix Oberholzer-Gee , and Mihir Desai review last year’s predictions for business, t
Youngme Moon , Felix Oberholzer-Gee , and Mihir Desai hand out their “awards” for 2019, including be
Youngme Moon , Felix Oberholzer-Gee , and Mihir Desai discuss the good and bad of modern airports. T
Youngme Moon , Felix Oberholzer-Gee , and Mihir Desai discuss some of the under-the-radar companies
In this special Thanksgiving edition taped a few days before the holiday, Youngme Moon , Felix Oberh
Youngme Moon , Felix Oberholzer-Gee , and Mihir Desai discuss several topics from a busy news week,
Youngme Moon , Felix Oberholzer-Gee , and Mihir Desai discuss the biggest money mistakes people make
Youngme Moon , Felix Oberholzer-Gee , and Mihir Desai discuss Google’s announcement that it’s buying
Youngme Moon , Felix Oberholzer-Gee , and Mihir Desai discuss a variety of trends from the world of
Youngme Moon , Felix Oberholzer-Gee , and Mihir Desai try to make sense of the firestorm sparked by
Youngme Moon , Felix Oberholzer-Gee , and Mihir Desai discuss the problem of household financial str
Does Space represent a real economic opportunity or are expensive endeavors like SpaceX a form of bi
After Hours is back for Season 3! Youngme Moon , Felix Oberholzer-Gee , and Mihir Desai debate which
It’s a wrap for Season 2, as Youngme Moon, Felix Oberholzer-Gee, and Mihir Desai head off on a summe
Wrapping up Season 2, Youngme Moon, Felix Oberholzer-Gee, and Mihir Desai count down the top stories
Youngme Moon, Felix Oberholzer-Gee, and Mihir Desai answer questions from listeners and end up discu
Youngme Moon, Felix Oberholzer-Gee, and Mihir Desai debate whether the FDA should crack down on teen
Youngme Moon, Felix Oberholzer-Gee, and Mihir Desai debate the pros and cons associated with the inc
Youngme Moon, Felix Oberholzer-Gee, and Mihir Desai discuss whether pharmaceutical players like the